HAL vs RXRX · P/E 9.3, $19.05B cap vs rev $58.8M
Halliburton Company (HAL) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
HAL does not have a complete income-statement cache yet.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
HAL currently screens at market cap $19.05B and trailing P/E 9.3. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the HAL and RXRX stock pages for the full models.
Not investment advice.